Hengrui Pharmaceutical (600276.SH): HRS-7172 tablets, etc. obtained drug clinical trial approval notice

Zhitongcaijing · 2d ago

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company and its subsidiaries received approval from the State Drug Administration to issue “Recent Drug Clinical Trial Approval Notice” for HRS-7172 tablets, adbelizumab injections, SHR-4610 injections, SHR-8068 injections, SHR-9839 (sc) for injections, bevacizumab SHR injections, HRS-4642 injections, HRS-6093 tablets, and HRS-7058 capsules, which will be launched clinical trials.

According to the “Drug Administration Law of the People's Republic of China” and related regulations, after review, the clinical trial applications for HRS-7172 tablets, adbelizumab injections, SHR-4610 injections, SHR8068 injections, SHR-9839 (sc) for injections, SHR-1826, bevacizumab injections, HRS-4642 injections, HRS-6093 tablets, and HRS-7058 capsules were approved for drug registration. Specifically, an open, multicenter IB/II clinical study on the safety, tolerability and efficacy of HRS-7172 combined with anti-tumor treatment in solid tumor participants.